Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06343805
Title A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ajax Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Cancer Center NOT_YET_RECRUITING Tampa Florida 33612 United States Details
University of Kansas Medical Center NOT_YET_RECRUITING Kansas City Kansas 66160 United States Details
Massachusetts General Hospital NOT_YET_RECRUITING Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute NOT_YET_RECRUITING Boston Massachusetts 02115 United States Details
Washington University School of Medicine NOT_YET_RECRUITING Saint Louis Missouri 63110 United States Details
David H. Koch Center for Cancer Care at Memorial Sloan Kettering NOT_YET_RECRUITING New York New York 10021 United States Details
Icahn School of Medicine at Mount Sinai RECRUITING New York New York 10029 United States Details
Levine Cancer Institute NOT_YET_RECRUITING Charlotte North Carolina 28204 United States Details
University of Cincinnati NOT_YET_RECRUITING Cincinnati Ohio 45221 United States Details
The Ohio State University Comprehensive Cancer Center NOT_YET_RECRUITING Columbus Ohio 43210 United States Details
MD Anderson Cancer Center NOT_YET_RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field